Global push to develop Covid-19 vaccine requires a big budget, say experts

Experts behind a global push to develop and roll out a vaccine and other treatment for the coronavirus say their ambitions require a big budget

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
AP Geneva
2 min read Last Updated : Jun 27 2020 | 7:23 AM IST

Experts behind a global push to develop and roll out a vaccine and other treatment for the coronavirus say their ambitions require a big budget.

The World Health Organization and its allies made a pitch for their ACT-Accelerator that aims to get a COVID-19 vaccine and treatment tools to the neediest people around the world, no matter the cost.

They were speaking a day before a European Union conference to drum up support and funds for the initiative that the United States has shunned so far.

Ultimately, WHO and partners say the project needs more than USD 31 billion through the end of 2021, for vaccines, therapeutics and diagnostics to fight a disease that has caused more than 9.6 million confirmed cases and killed more than 490,000 people worldwide.

If we don't rally now, the human costs and the economic pain will deepen, said Dr. Ngozi Okonjo-Iweala, one of the WHO chief's special envoys for the initiative. So though these numbers sound big, they're not when we think of the alternatives.

Just think of the trillions of dollars that have had to be spent in order to stimulate economies back, she said. If we spend billions now, we'll be able to avoid spending trillions later.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccinehealthcare

First Published: Jun 27 2020 | 1:14 AM IST

Next Story